Bayer's Off-Label Yaz Marketing Violated FCA: Watchdog

Law360, New York (December 14, 2011, 4:57 PM EST) -- A pharmaceutical company watchdog accused Bayer Schering Pharma AG of marketing its Yasmin and Yaz contraceptives for unapproved purposes and causing doctors to seek Medicaid reimbursements for off-label prescriptions of those drugs, according to court documents unsealed Monday.

In a complaint filed under seal in October 2010 in Texas federal court, relator Pharma Fraud Watch LLC alleges that Bayer violated the False Claims Act by knowingly causing pharmacists and doctors to file false federal government claims by marketing Yaz and Yasmin for uses the U.S. Food...
To view the full article, register now.




Case Information

Case Title

USA v. Bayer Schering Pharma AG, et al.,

Case Number



Texas Eastern

Nature of Suit

Other Statutory Actions


Marcia A. Crone

Date Filed

October 22, 2010

Law Firms


Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.